ReviewNPJ breast cancer2025
Radiation therapy for lobular breast cancer: opportunities and challenges for leveraging radiosensitivity.
Review in NPJ breast cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Toward targeted therapeutics for lobular breast cancer.The Journal of clinical investigation · 2026Review
- Altered MDC1 Interactions and Dysfunctional DNA Repair in Lobular Breast Cancer Confers Sensitivity to PARP Inhibition.Cancer research · 2026Article
- From local control to immune modulation: hypofractionated radiotherapy as a backbone for cancer immunotherapy.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Invasive lobular carcinoma (ILC) is the most common special histological subtype of breast cancer, accounting for 15% of cases. ILC has unique clinical and molecular characteristics yet is treated largely agnostic of subtype. We explore challenges and opportunities in treating ILC, focusing on the underexplored sensitivity of ILC to ionizing radiation therapy (XRT). While ILC presents forms of resistance to chemotherapy and endocrine therapy, clinical data support that ILC have a distinct vulnerability to XRT, with XRT reducing recurrence rates in postsurgical contexts; molecular analyses identify putative defects in DNA repair in ILC that may underpin XRT sensitivity. However, gaps in the literature limit our understanding of XRT efficacy in ILC, and current treatment guidelines that inadequately address ILC-specific considerations limit XRT optimization. Future research should prioritize new clinical and mechanistic analyses of XRT efficacy, toward optimizing patient care and harnessing the full therapeutic potential of XRT for ILC.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.